An Open Label Dose Escalation Phase 1 Clinical Trial of Retinal Gene Therapy for Choroideraemia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 4
- 主要终点
- Visual acuity
研究概览
简要总结
-
Primary objective: To assess the safety and tolerability of the AAV.REP1 vector, administered at two different doses to the retina in 12 patients with a diagnosis of choroideremia.
-
Secondary Objective: To identify any therapeutic benefit as evidenced by a slowing down of the retinal degeneration assessed by functional and anatomical methods in the treated eye compared to the control eye 24 months after gene delivery.
详细描述
Detailed description may be found in the following scientific publication:
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial, The Lancet, Volume 383, Issue 9923, Pages 1129 - 1137 (29 March 2014).
Links: www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62117-0/abstract ; http://dx.doi.org/doi:10.1016/S0140-6736(13)62117-0
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Participant is willing and able to give informed consent for participation in the study,
- •Male aged 18 years or above,
- •Diagnosed with choroideraemia and in good health,
- •Active disease with SLO changes visible within the macula region,
- •Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study,
- •Vision at least 6/60 or better in the study eye.
排除标准
- •Female and child participants (under the age of 18),
- •Men unwilling to use barrier contraception methods, if relevant,
- •Previous history of retinal surgery or ocular inflammatory disease (uveitis),
- •Grossly asymmetrical disease or other ocular morbidity which might confound use of the fellow eye as a long-term control,
- •Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study,
- •Participants who have participated in another research study involving an investigational product in the previous 12 weeks.
研究组 & 干预措施
Dose 1
Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.
干预措施: rAAV2.REP1 (Drug)
Dose 2
Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.
干预措施: rAAV2.REP1 (Drug)
结局指标
主要结局
Visual acuity
时间窗: 6 months
Best corrected visual acuity, following cataract surgery if indicated
次要结局
- Microperimetry, OCT and fundus autofluorescence(24 months)